Nippon Kayaku Co., Ltd.
Notice on the Status of Share Buyback
Based on a board resolution dated May 12, 2026, we conducted a share buyback of common stock. From June 1 to June 30, 2026, the cumulative number of shares acquired through market purchases was 1,244,100 shares, with a total acquisition value of 2,604,697,050 yen. The cap is 13,000,000 shares and 150,000,000,000 yen.
Key Figures
- Total number of shares acquired: 1,244,100 shares
- Total acquisition value: 2,604,697,050 yen
- Maximum number of shares for acquisition: 13,000,000 shares (limit)
AI要約
Section Heading
Nihon Kagaku Pharmaceutical Co., Ltd. continues to disclose share buybacks with the aim of enhancing shareholder value. From June 1 to June 30, 2026, we acquired 1,244,100 shares of common stock through market purchases, with a total acquisition value of approximately 260 million yen. In the prior resolution, the cap was set at 13,000,000 shares and 15,000,000,000 yen, with the acquisition period planned from May 13, 2026, to March 31, 2027. Acquisition is contemplated with consideration for the total number of issued shares.
Section 2 heading
This acquisition is conducted through market purchases, and cumulative progress toward the cap remains within room. Further acquisitions will be considered depending on the policy and market conditions. The purpose is to improve capital efficiency and strengthen shareholder returns, with execution anticipated at an appropriate timing and scale.
日本化药株式会社
Company overview · Stock price · Financial data · All IR
